HomeAI · summaries
Storia in 2 fonti
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
- ·
benzinga.com
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Novartis
Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.